Dacomitinib (D) Versus Erlotinib (E) in Patients (pt) with EGFR-mutated (mu) Advanced Non-small Cell Lung Cancer (NSCLC): Analyses from a Randomized, Phase 2 Trial

被引：0
|
作者：
Ramalingam, S. [1 ]
Blackhall, F. [2 ]
Rosell, R. [3 ]
Mok, T. [4 ]
Boyer, M. [5 ]
Liang, J. [6 ]
O'Connell, J. [6 ]
Wang, T. [6 ]
Taylor, I. [6 ]
机构：
[1] Emory Univ, Atlanta, GA 30322 USA
[2] Christie Hosp, Manchester, Lancs, England
[3] Catalan Inst Oncol, Barcelona, Spain
[4] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
[5] Sydney Canc Ctr, Camperdown, NSW, Australia
[6] Pfizer Oncol, Groton, CT USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S203 / S203
页数：1
相关论文
共 50 条
  • [1] Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials
    Ramalingam, S. S.
    O'Byrne, K.
    Boyer, M.
    Mok, T.
    Jaenne, P. A.
    Zhang, H.
    Liang, J.
    Taylor, I.
    Sbar, E. I.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2016, 27 (03) : 423 - 429
  • [2] A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC)
    Stinchcombe, T. E.
    Janne, P. A.
    Wang, X.
    Bertino, E. M.
    Weiss, J. M.
    Bazhenova, L.
    Gu, L.
    Lau, C. J.
    Paweletz, C. P.
    Jaslowski, A. J.
    Gerstner, G. J.
    Baggstrom, M. Q.
    Graziano, S. L.
    Beardenlii, J.
    Vokes, E. E.
    ANNALS OF ONCOLOGY, 2018, 29 : 522 - 522
  • [3] Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials (vol 27, pg 423, 2016)
    Ramalingam, S. S.
    O'Byrne, K.
    Boyer, M.
    Mok, T.
    Janne, P. A.
    Zhang, H.
    Liang, J.
    Taylor, I.
    Sbar, E. I.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2016, 27 (07) : 1363 - 1363
  • [4] Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer
    Santarpia, Mariacarmela
    Menis, Jessica
    Chaib, Imane
    Cao, Maria Gonzalez
    Rosell, Rafael
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (09) : 831 - 840
  • [5] Estrogen Metabolism in Patients with EGFR-Mutated and ALK-Mutated Non-Small Cell Lung Cancer (NSCLC)
    Bodor, J. N.
    Treat, J.
    Krzizike, D. D.
    Zawislak, C. L.
    Vanderveer, L.
    Yulis, M.
    Chau, A.
    Ross, E. A.
    Andrews, A. J.
    Clapper, M. L.
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (02) : S18 - S19
  • [6] Plasma metabolite biomarkers for EGFR-mutated non-small cell lung cancer (NSCLC)
    Thamlikitkul, Lucksamon
    Manocheewa, Siriphan
    Limjiasahapong, Suphitcha
    Wanichthanarak, Kwanjeera
    Panya, Atikorn
    Poungvarin, Naravat
    Pomyen, Yotsawat
    Khoomrung, Sakda
    CANCER RESEARCH, 2024, 84 (06)
  • [7] A Delphi Consensus on TKI Sequencing in Treating Advanced EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)
    Wehler, T.
    Hirsh, V.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1043 - S1043
  • [8] Phase I trial of vorinostat in combination with erlotinib in advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations after erlotinib progression
    Reguart, N.
    Cardona, A. F.
    Isla, D.
    Cardenal, F.
    Palmero, R.
    Carrasco-Chaumel, E.
    Rolfo, C.
    Massuti, B.
    Moran, T.
    Rosell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Depression and Inflammation in Patients with EGFR-Mutated Non-Small Cell Lung Cancer
    Cardona, A.
    Arrieta, O.
    Rojas, L.
    Zatarain-Barron, Z.
    Ricaurte, L.
    Ruiz-Patino, A.
    Martin, C.
    Carranza, H.
    Vargas, C.
    Otero, J.
    Corrales, L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S871 - S871
  • [10] Progress in individualized treatment for EGFR-mutated advanced non-small cell lung cancer
    Inoue, Akira
    PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES, 2020, 96 (07): : 266 - 272
12345